Artimplant applies for its own bankruptcy

The Board of Directors and the CEO of Artimplant AB (publ) have decided to apply
for its own bankruptcy.

The reasons behind the insolvency and the liquidity problems are related to the
ongoing litigations in the USA, where Artimplant has been sued by approx. 50
patients who claims they have been injured by the CMC Spacer, and the ongoing
Arbitration in Sweden, which has been initiated by Artimplant to determine which
insurance company or insurance broker are responsible for each claim related to
the litigations in the USA.

The ongoing disputes have had a negative impact on Artimplants sales and have
also occupied the management’s recourses which have resulted negatively on the
company’s development.

Parallel to this there has been an intensive work to try to find a new main
shareholder, attract new capital to the company and to find new improved
distribution channels. The Board has been in discussions with potential
investors and other interested parties but the ongoing disputes substantially
reduced the interested to invest in the company. The Board has also discussed a
possible new right issue of shares but during the current circumstances decided
this will not be possible to achieve.

Taking all this into consideration it has not been possible to fulfil the
earlier signed agreement with Tiller.

The Board and the CEO has therefore reached the conclusion to apply for
Artimplants bankruptcy.

Västra Frölunda, August 1, 2013

The Board of Directors

For additional information, please contact:
Håkan Johansson, Chairman of the board, phone +46 (0)705 14 21 57

Kjell Thörnbring, CEO, phone +46 (0)703 11 90 25,
kjell.thornbring@artimplant.com

Artimplant
Artimplant is a biomaterials company focused on solutions to problems in
orthopedic. We restore health through the development, production and marketing
of degradable implants that regenerate body functions and improve quality of
life. Our products, made from Artelon®, meet unmet clinical needs and are
marketed in a growing number of therapy areas. Artimplant produces implants for
treatment of osteoarthritis in hands and feet, for shoulder and other soft
tissue injuries.

Artimplant is a public company listed on the OMX Nordic Exchange Stockholm in
the Small Cap segment and in the healthcare sector.

Forward-looking statements
This press release contains forward-looking statements as defined in the U.S.
Private Securities Litigation Reform Act of 1995. Readers are cautioned not to
place undue reliance on these forward-looking statements. Actual results may
differ materially from those indicated by these forward-looking statements as a
result of risks and uncertainties impacting the Company's business including
increased competition; the ability of the Company to expand its operations and
to attract and retain qualified professionals; technological obsolescence;
general economic conditions; and other risks detailed from time to time in the
Company's filings.

This is information which Artimplant shall make public pursuant to the Swedish
Financial Instruments Act and the Swedish Securities Exchange and Clearing
Operations Act and/or stock market agreements. Information was made available
for publication on August 1, 2013 at 8:45 AM (CET).